ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-OR134

Efficacy and Safety of Difelikefalin in Patients Undergoing Hemodialysis with Pruritus: Results from a Phase 3 Randomized, Controlled Study (KALM-1)

Session Information

  • High-Impact Clinical Trials
    November 08, 2019 | Location: Ballroom C, Walter E. Washington Convention Center
    Abstract Time: 02:45 PM - 03:00 PM

Category: Dialysis

  • No subcategory defined

Authors

  • Fishbane, Steven, Northwell Health, Commack, New York, United States
  • Jamal, Aamir Z., North America Research Institute, San Dimas, California, United States
  • Wen, Warren, Cara Therapeutics, Inc., Stamford, Connecticut, United States
  • Munera, Catherine, Cara Therapeutics, Inc., Stamford, Connecticut, United States
  • Menzaghi, Frederique, Cara Therapeutics, Inc., Stamford, Connecticut, United States
Background

There is an unmet need for effective treatments for pruritus associated with chronic kidney disease (CKD-aP or uremic pruritus), a debilitating condition prevalent in patients undergoing hemodialysis (HD). Difelikefalin (DFK; CR845) is a novel, peripherally restricted kappa opioid receptor (KOR)-specific agonist in development for treatment of pruritus. Here we report on the first Phase 3 study of DFK in HD patients with CKD-aP.

Methods

Patients with moderate-to-severe CKD-aP undergoing HD (N=377) were randomized 1:1 to receive an IV bolus of DFK 0.5 mcg/kg (N=189) or placebo (PBO) (N=188), thrice weekly post dialysis, over 12 weeks. The primary endpoint was the proportion of patients achieving ≥3-point improvement from baseline (BL) to Week 12 in the weekly mean of 24-hr daily Worst Itching Intensity Numerical Rating Scale (WI-NRS) scores. Secondary endpoints included the change in itch-related QoL measured by 5-D Itch and Skindex-10 questionnaires and the proportion of patients achieving ≥4-point WI-NRS score improvement from BL to Week 12. Safety was assessed based on vital signs, clinical laboratory results, ECG, and adverse event (AE) reporting.

Results

The primary and all secondary efficacy endpoints were met. BL mean WI-NRS scores were 7.1 and 7.3 in DFK and PBO groups. Percentages of patients with ≥3-point improvement and ≥4-point improvement in mean WI-NRS scores at Week 12 were 51% vs 28% (p<0.001; odds ratio (OR) 2.7) and 39% vs 18% (p<0.001, OR 2.9) for DFK vs PBO. Separation from PBO in WI-NRS score change from baseline was observed at Week 1. All QoL measures were significantly improved vs PBO (p<0.001). Serious AE incidence was similar for DFK vs PBO; most common treatment emergent AEs were diarrhea (9.5% vs 3.7%), dizziness (6.9% vs 1.1), and vomiting (5.3% vs 3.2%).

Conclusion

This study demonstrated that DFK significantly reduced itch intensity in HD patients. Patients treated with DFK were about 3 times (based on OR) more likely to have a clinically meaningful reduction in itch intensity vs PBO and had significant improvements in QoL. DFK was generally well tolerated with an acceptable safety profile. DFK could represent an important advance for treatment of pruritus in HD patients.

Funding

  • Commercial Support – Cara Therapeutics, Inc.